Clinical Trials Arena on MSN7d
J&J’s NSCLC combo projected to extend survival by one year over Tagrisso
Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...
EurekAlert!8mon
Survival curve of the studying IEI cohort who underwent allogeneic HCT alongside RTC with alemtuzumab (IMAGE)
The solid line and the dashed line show OS and GEFS curves, respectively ... were defined as failure events for GEFS. OS, overall survival; GEFS, graft-versus-host disease-free, event-free ...